Compare Nu Holdings Ltd (NU) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs Zoetis Inc — how do they compare? Nu Holdings Ltd trades at $13.48 (market cap $65.94B), while Zoetis Inc trades at $72.69 (market cap $31.14B). The key difference: Nu Holdings Ltd is far larger — about 2.1× Zoetis Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals.
| NU | ZTS | |
|---|---|---|
Market Cap | $65.94B | $31.14B |
Sector | Financials | Health |
52-Week High | $18.76 | $156.76 |
52-Week Low | $11.60 | $71.91 |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU stock trades at $13.47, down 2.81% over the past day, with technical indicators signaling a bearish trend. The company reported strong fundamentals, with revenue growing from $3.0B in 2022 to $10.63B in 2025 and net income turning positive to $2.87B. Recent earnings have shown mixed results, with two misses in the last three quarters, but Q2 2026 results are anticipated as a potential catalyst. Analyst consensus remains bullish with a $14.98 price target, though technical weakness persists near support at $13.
The outlook for NU is supported by robust revenue growth and profitability improvements, but near-term risks include competitive pressures and technical bearishness. Upside potential exists if Q2 earnings beat expectations, while failure to meet targets could exacerbate selling pressure. Investors should weigh strong fundamentals against current market sentiment and upcoming earnings.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
